Observational cohort study: deprivation and access to anti-dementia drugs in the UK

被引:51
|
作者
Cooper, Claudia [1 ]
Lodwick, Rebecca [2 ]
Walters, Kate [2 ]
Raine, Rosalind [3 ]
Manthorpe, Jill [4 ]
Iliffe, Steve [2 ,5 ]
Petersen, Irene [2 ]
机构
[1] UCL, Div Psychiat, London, England
[2] UCL, Res Dept Primary Care & Populat Hlth, London, England
[3] UCL, Dept Appl Hlth Res, London, England
[4] Kings Coll London, Social Care Workforce Res Unit, London, England
[5] UK Dementias & Neurodegenerat Dis Res Network, London, England
关键词
dementia; healthcare disparities; cholinesterase inhibitor; older people; SOCIOECONOMIC-STATUS; DEMENTIA; CARE; POPULATION; PREVALENCE; PERIODS; LEVEL;
D O I
10.1093/ageing/afv154
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background: UK National Dementia Strategies prioritise fair access to dementia treatments for the whole population. We investigated for the first time inequalities in NHS national dementia prescribing and how they have varied between UK countries and over time. Method: we investigated the association between Townsend deprivation score and anti-dementia drug prescribing in 77,045 dementia patients from UK primary care records from 2002 to 2013. Results: we included 77,045 patients with recorded dementia diagnosis or anti-dementia drug prescription. Least deprived patients were 25% more likely to be initiated on anti-dementia drugs than the most deprived (adjusted incidence rate ratio 1.25, 95% confidence interval 1.19-1.31). This was driven by data from English practices where prescribing rates were consistently lower in more deprived patients compared with Scotland, Northern Ireland and Wales, where prescribing was not related to deprivation quintile. Compared with English practices, anti-dementia medication was prescribed more often in Northern Irish (1.81, 1.41-2.34) and less in Welsh practices (0.68, 0.55-0.82), with a trend towards more prescribing in Scottish practices (1.14, 0.98-1.32). Drug initiation rates were also higher in younger people and men. Conclusion: four years after the English National Dementia Strategy, there is no evidence that the Strategy's key objective of reducing treatment inequalities is being achieved. Higher overall anti-dementia drug prescribing in Scottish and Northern Irish practices, and differing clinical guidelines in Scotland from other UK countries might explain greater equality in prescribing in these countries. Strategies to offer treatment to more deprived people with dementia in England are needed.
引用
收藏
页码:148 / 154
页数:7
相关论文
共 50 条
  • [31] What is new in the methods to develop new anti-dementia drugs
    Allain, H.
    Bentue-Ferrer, D.
    Belliard, S.
    Reymann, J. M.
    Merienne, M.
    Tribut, O.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2001, 15 : 53 - 53
  • [32] Concomitant use of anti-dementia drugs with psychotropic drugs in Norway-a population-based study
    Langballe, Ellen Melbye
    Engdahl, Bo
    Selbk, Geir
    Nordeng, Hedvig
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 (12) : 1319 - 1326
  • [33] Alarming arbitrariness in EU prescription and reimbursement criteria for anti-dementia drugs
    Voshaar, RCO
    Burns, A
    Rikkert, MGMO
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2006, 21 (01) : 29 - 31
  • [34] The Effects of Anti-Dementia and Nootropic Treatments on the Mortality of Patients with Dementia: A Population-Based Cohort Study in Taiwan
    Wu, Chen-Yi
    Hu, Hsiao-Yun
    Chow, Lok-Hi
    Chou, Yiing-Jenq
    Huang, Nicole
    Wang, Pei-Ning
    Li, Chung-Pin
    PLOS ONE, 2015, 10 (06):
  • [35] Anti-dementia drugs and Repetitive Transcranial Magnetic Stimulation in neurocognitive disorders
    Nina-Estrella, Rose E.
    Mena, William Marte
    Komatsu, Hanae
    Perez, Juana Paula
    INTERNATIONAL PSYCHOGERIATRICS, 2024, 36 : 135 - 136
  • [36] Development of anti-dementia drugs for Alzheimer's disease: Present and future
    Nabeshima, T
    Yamada, K
    MAPPING THE PROGRESS OF ALZHEIMER'S AND PARKINSON'S DISEASE, 2002, 51 : 223 - 228
  • [37] Measuring the effects of anti-dementia drugs in patients with Alzheimer's disease
    Curran, S
    Wattis, JP
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 1997, 12 (04) : 347 - 359
  • [38] No evidence exists that "anti-dementia" drugs modify disease or improve outcome
    Gordon, Peter J.
    BMJ-BRITISH MEDICAL JOURNAL, 2014, 348
  • [39] Effects of anti-dementia drugs on the sleep wake-cycle in rats
    Ishida, Takayuki
    Takeda, Yasuhiro
    Kamei, Chiaki
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2008, 106 : 234P - 234P
  • [40] Animal models of Alzheimer's disease and evaluation of anti-dementia drugs
    Yamada, K
    Nabeshima, T
    PHARMACOLOGY & THERAPEUTICS, 2000, 88 (02) : 93 - 113